Organogenesis Holdings (Avista Healthcare Public Acquisition) ^{Priced, Nasdaq: ORGO}

We are a newly organized blank check company incorporated on December 4, 2015. We have not identified any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with respect to identifying any business combination target, though our initial focus will be to acquire and operate a North American or European healthcare-related business. Our founders are two of the founders and managing partners of Avista, a middle market private equity firm focused on control buyout and growth investments in the healthcare, communications and industrial sectors, with offices in New York, Houston and London. Thompson Dean, our Executive Chairman, and David Burgstahler, our President and CEO, co-founded Avista in 2005 and have worked together for over 20 years. Over the past 10 years, Avista has raised four private equity funds and had approximately $6 billion in assets under management as of June 30, 2016. We expect that Avista will raise additional funds and / or successor funds in the future. Our management team has significant experience sourcing, analyzing, acquiring and operating healthcare related businesses. Since inception, Avista funds have invested in 15 healthcare portfolio companies.